检索结果-南通市图书馆

Progress in systemic therapy of advanced hepatocellular carcinoma

在线全文

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2016年第29期22卷 6582-6594页

作者： Xin-Lei Gong Shu-kui qin Chinese People’s Liberation Army Cancer Center Bayi Hospital

Primary liver cancer, mainly consisting of hepatocellular carcinoma(HCC), is one of common malignancies worldwide, and prevalent among the Chinese population. A diagnosis of early stage HCC has proven to be very difficult because of its insidious feature in onset and development. At the time of diagnosis, most HCC cases are locally advanced and/or distant metastatic, which results in difficulty to be treated and poor prognosis. For advanced HCC, systemic therapy is frequently adopted as an important palliative method. In recent years, clinical studies and observations have often reported about systemic anti-cancer therapy of advanced HCC, including molecular target therapy, systemic chemotherapy and immunotherapy. In this article, we review these treatment modalities to provide a reference for clinicians.

关键词： Hepatocellular carcinoma Systemic therapy Molecular targeted therapy Chemotherapy Progress

Type Ⅰ neurofibromatosis with spindle cell sarcoma: A case report

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Clinical Cases 2019年第19期7卷 3104-3110页

作者： Yu Zhang Jiao-Jiao Chao Xiu-Feng Liu Shu-kui qin BaYi Hospital Affiliated to Nanjing University of Chinese Medicine Nanjing University of Chinese MedicineNanjing 210000Jiangsu ProvinceChina Department of Oncology BaYi Hospital Affiliated to Nanjing University of Chinese MedicineNanjing 210000Jiangsu ProvinceChina

BACKGROUND Neurofibromatosis type Ⅰ(NF1) is the most frequent subtype of neurofibromatosis. Its related tumor-suppressor syndromes are characterized by a predisposition to multiple tumor types and other disorder presentations. In addition, the incidence of tumors is much higher in patients with neurofibromatosis type Ⅰ. However, there are very few reports at home and abroad on this topic. Here, we present a case of NF1 with spindle cell *** SUMMARY A 50-year-old male was found to have a right axillary mass for 20 *** examination found cafe-au-lait spots on many parts of the skin,rounded nodules in the skin, a bulge in the right armpit, touching a lump(10 cm× 6 cm, hard, unclear boundary, poor mobility, local tenderness). The anterior side of the thigh felt weakened on the opposite side;in the right groin a swollen lymph node(hard, clear border, good mobility, local tenderness). According to the results of positron emission tomography/computed tomography, puncture pathology and immunohistochemistry, genetic testing, a diagnosis of NF1 with spindle cell sarcoma was confirmed. According to the genetic testing result, the patient was given a targeted treatment with *** Surgery, chemotherapy and radiotherapy are the main treatment methods of NF1. However, with the continuous progress of molecular biology research,molecular targeted therapy may bring benefits for patients.

关键词： Neurofibromatosis Type Ⅰ Spindle cell sarcoma Targeted therapy Crizotinib Case report

A hypothesis study on a four-period prevention model for high altitude disease

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Military Medical Research 2018年第2期5卷 183-188页

作者： Xian-Sheng Liu Xiang-Rong Yang Lu Liu Xian-kui qin Yu-Qi Gao Institute of Medicine and Hygienic Equipment for High Altitude Region College of High Altitude Military MedicineThird Military Medical UniversityNo.30 Gaotanyan StreetShapingba DistrictChongqing 400038China Department of Medical Affairs The 5th Hospital of the Chinese PLANo.893 Shengli StreetXingqing DistrictYinchuanNingxia 750003China Key Laboratory of High Altitude Environmental Medicine Third Military Medical UniversityMinistry of EducationNo.30 Gaotanyan StreetShapingba DistrictChongqing 400038China Key Laboratory of High Altitude Medicine of PLA No.30 Gaotanyan StreetShapingba DistrictChongqing 400038China Department of Health Service Training Base of Health ServiceThird Military Medical UniversityNo.30 Gaotanyan StreetShapingba DistrictChongqing 400038China Department of Outpatient PLA No.96819 UnitNo.2 Heping RoadChaoyang DistrictBeijing 100085China

Background:High altitude disease(HAD)can reduce combat effectiveness and damage the health of soldiers at high *** objective of this hypothesis study is to build a four-period prevention model for high altitude disease that can be applied at high altitudes of over 3000 *** of the hypothesis:We divided the time at high altitude into nine periods,with three stages from the ascent preparation to the descent to the plain,and applied a continuous dynamic and systematic four-period prevention model across the nine *** period of three stages has its own different measures and targets high altitude health care services for the prevention of high altitude disease.A standard four-period prevention model for high altitude disease was constructed for the high altitude health services at the population *** the hypothesis:Our hypothesized HAD prevention model represents a continuous dynamic and systematic four-period prevention model across the nine *** hypothesis can be tested from three *** first one is assessment of soldiers’operating *** second is comparison of the long-term high altitude population health basic data and development and utilization of big *** third is descent population health status comparative study and historical retrospective study on ***:As we know,it is necessary to protect soldiers’health through the ascent and *** the standard four-period model,we can protect soldiers’health by preventing high altitude diseases,screening the susceptible population,securely tracking their location and maintaining soldiers’health statuses;we also maintain their operational capabilities,eliminate their psychological fears and ease their family troubles.

关键词： High altitude disease High altitude health service Prevention model

Giant hepatobiliary cystadenoma in a male with obvious convex papillate

在线全文

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2009年第15期15卷 1906-1909页

作者： Zhao-Wei Qu Qiang He Ren Lang Fei Pan Zhong-kui Jin qin-Song Sheng Dong Zhang Xiao-Sheng Zhang Da-Zhi Chen Department of Hepatobiliary and Pancreatospleenic Surgery Beijing Chaoyang Hospital Affiliated to CapitalMedical University Beijing 100020 China

Hepatobiliary cystadenoma that is most often found in is an uncommon lesion middle-aged women and difficult to diagnose preoperatively. Here, we report a case of giant hepatobiliary cystadenoma in a male patient with obvious convex papillate. On the basis of imaging examinations, the patient was diagnosed as hepatobiliary cystadenoma prior to operation. Left hepatectomy was performed and the patient was symptom-free during a 6-too follow-up period, suggesting that imaging examination is the major diagnostic method of hepatobiliary cystadenoma, and operation is its best treatment modality.

关键词： Hepatobiliary cystadenoma Liverneoplasm Biliary ductal tumour Diagnosis Treatment

Influence of acute hyperglycemia in human sepsis on inflammatory cytokine and counterregulatory hormone concentrations

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2003年第8期9卷 1824-1827页

作者： Wen-kui Yu Wei-qin Li Ning Li Jie-Shou Li, Medical College of Nanjing University, Research Institute of General Surgery, Jinling Hospital, Nanjing 210002, Jiangsu Province, China Medical College of Nanjing University Research Institute of General Surgery Jinling Hospital Nanjing 210002 Jiangsu Province China. yudrnj@***

AIM: In human sepsis, a prominent component of the hypermetabolite is impaired glucose tolerance (IGT) and hyperglycemia. Elevations in plasma glucose concentration impair immune function by altering cytokine production from macrophages. We assessed the role of glucose in the regulation of circulating levels of insulin, glucagon, cortisol,IL-6 and TNF-α in human sepsis with normal or impaired glucose ***: According to the results of intravenous glucose tolerance test, forty patients were classified into two groups: control group (n=20) and IGT group (n=20).Plasma glucose levels were acutely raised in two groups and maintained at 15 mmol/L for 3 hours. Plasma insulin,glucagon and cortisol levels were measured by radioimmunoassay, the levels of TNF-α and IL-6 were detected by ***: In IGT group, the fasting concentrations of plasma glucose, insulin, glucagon, cortisol, IL-6 and TNFα levels were significantly higher than those in control group (P＜0.05). During clamp, the control group had a higher average amount of dextrose infusion than the IGT group (P＜0.01). In control group, plasma insulin levels rose from a basal value to a peak at an hour (P＜0.05) and maintained at high levels. Plasma glucagon levels descended from a basal value to the lowest level within an hour (P＜0.01)and low levels were maintained throughout the clamp. In IGT group, plasma insulin was more significantly elevated (P＜0.01), and plasma glucagon levels were not significantly declined. Plasma cortisol levels were not significantly changed in two groups. In control group, plasma IL-6 and TNF-α levels rose (P＜0.01) within 2 hours of the clamp and returned to basal values at 3 hours. In IGT group, increased levels of plasma cytokine lasted longer than in control group (3 hours vs. 2 hours, P＜0.05), and the cytokine peaks of IGT group were higher (P＜0.05) than those of control ***: Acute hyperglycemia pricks up hyperinsulinemia and increases circulating cytokine con

关键词：高血糖症脓毒病细胞因子激素葡萄糖耐量降低

Clinical practice guidelines for the treatment of primary liver cancer with integrative traditional Chinese and Western medicine

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Integrative Medicine 2018年第4期16卷 236-248页

作者： Chang-quan Ling Jia Fan Hong-sheng Lin Feng Shen Zhen-ye Xu Li-zhu Lin Shu-kui qin Wei-ping Zhou Xiao-feng Zhai Bai Li qing-hui Zhou Department of Integrative Oncology Changhai Hospital of Traditional Chinese MedicineSecond Military Medical UniversityShanghai 200433China Department of Liver Surgery and Transplantation Liver Cancer InstituteZhongshan HospitalFudan UniversityShanghai 200032China Department of Oncology Guang'anmen HospitalChina Academy of Chinese Medical SciencesBeijing 100053China Department of Hepatobiliary Surgery Eastern Hepatabiliary Surgery HospitalSecond Military Medical UniversityShanghai 200433China Department of Oncology Longhua HospitalShanghai University of Traditional Chinese MedicineShanghai 200032China Department of Oncology First Affiliated Hospital of Guangzhou University of Chinese MedicineGuangzhou 510405China Cancer Center of Bayi Hospital Nanjing University of Chinese Medicine210002China Department of Rehabilitative Medicine Changhai Hospital of Traditional Chinese MedicineSecond Military Medical UniversityShanghai 200433China Department of Acupuncture-Moxihustion and Tuina Changhai Hospital of Traditional Chinese MedicineSecond Military Medical UniversityShanghai 200433China

Traditional Chinese medicine （TCM） is an important part of the treatment of primary liver cancer （PLC） in China; however, the current instructions for the integrative use of traditional Chinese and Western medicine for PLC are mostly based on expert opinion. There is no evidence-based guideline for clinical prac-tice in this field. Therefore, the Shanghai Association of Chinese Integrative Medicine has established a multidisciplinary working group to develop this guideline, which focuses on the most important questions about the use of TCM during PLC treatment. This guideline was developed following the method- ological process recommended by the World Health Organization Handbook for Guideline Development. Two rounds of questionnaire survey were performed to identify clinical questions; published evidence was searched; the Grading of Recommendations Assessment, Development and Evaluation approach was used to evaluate the body of evidence; and recommendations were formulated by combining the quality of evidence, patient preferences and values, and other risk factors. The guideline was written based on the Reporting Items for Practice Guidelines in Healthcare tool. This guideline contains 10 recommendations related to 8 questions, including recommendations for early treatment by TCM after surgery, TCM combined with transcatheter arterial chemoembolization for advanced PLC, TCM drugs for external use, and acupuncture and moxibustion therapy.

关键词： Primary liver cancerClinical practice guidelines Traditional Chinese medicineIntegrative medicine

三磷酸腺苷对国人食管癌Eca-109和肝癌SMMC-7721细胞增殖的影响

在线全文

学校读者我要写书评

暂无评论

中国药理学通报 2006年第1期22卷 31-34页

作者：秦葵任雷鸣河北医科大学药学院药理学研究室河北石家庄050017

目的研究三磷酸腺苷（ATP）对人食管癌细胞株Eca-109和人肝癌细胞株SMMC-772l细胞增殖的影响。方法采用MTT法测定ATP、腺苷（ADO）和三磷酸尿苷（UTP）抑制肿瘤细胞增殖的作用，Wrights-Giemsa染色观察细胞形态学的改变。结果ATP（0.0... 详细信息

目的研究三磷酸腺苷（ATP）对人食管癌细胞株Eca-109和人肝癌细胞株SMMC-772l细胞增殖的影响。方法采用MTT法测定ATP、腺苷（ADO）和三磷酸尿苷（UTP）抑制肿瘤细胞增殖的作用，Wrights-Giemsa染色观察细胞形态学的改变。结果ATP（0.03～0．3mmol·L^-1）和ADO（0．1～0.3mmol·L^-1）可不同程度地抑制Eca-109和SMMC-7721的增殖，ATP对两株肿瘤细胞增殖的抑制作用均强于ADO。ATP和ADO对Eca-109细胞的最大抑制率分别为86．36％和29.88％，IC50分别为0．056和0.823mmol·L^-1；对SMMC-7721细胞的最大抑制率分别为82．06％和52．84％，IC50分别为0．218和0．517mmol·L^-1。UTP对Eta-109细胞有很弱的抑制增殖作用，最大抑制率仅为18．27％；对SMMC-7721无抗增殖作用．两株细胞经高浓度（0．3mmol·L^-1）ATP处理后，部分SMMC-7721细胞形态出现了明显的凋亡特征，而Eta-109细胞凋亡特征不明显。结论ATP具有较强的抗Eca-109细胞增殖作用，其抗增殖作用主要由ATP自身所致，代谢产物ADO也具有一定的作用；而对于SMMC-772l细胞，ATP可能较大程度地通过降解为ADO而发挥抗增殖作用．

关键词：三磷酸腺苷腺苷三磷酸尿苷抗肿瘤作用细胞凋亡

Antioxidant and antidiabetic chemical constituents of Scindapsus aureus Flowers

在线全文

学校读者我要写书评

暂无评论

Antioxidant and antidiabetic chemical constituents of Scinda...

Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer:a randomized phase Ⅲ ARTIST trial

中国化学会第十届全国天然有机化学学术会议

作者： Zhi-Gang Tai An-Yi Chen Ben-kui qin Hui-Ling Chen Zhong-Tao Ding Faculty of Science and Life Technology Kunming University of Science and Technology

＜正＞In the present study,it was discovered that the soluble fraction of Scindapsus aureus flowers was a rich source of antioxidant and antidiabetic agents with bioactivity-guided fractionation,due to its significant antioxidant and antidiabetic ***-one chemical constituents were isolated from *** flowers for the first *** powerful antioxidants（phenolics）,such as

关键词：

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

Chinese Journal of Cancer 2011年第10期30卷 682-689页

作者： Zhong-Zhen Guan Jian-Ming Xu Rong-Cheng Luo Feng-Yi Feng Li-Wei Wang Lin Shen Shi-Ying Yu Yi Ba Jun Liang Dong Wang Shu-kui qin Jie-Jun Wang Jing He Chuan Qi Rui-Hua Xu State Key Laboratory of Oncology in South China Guangzhou Guangdong 510060 P. R. China Sun Yat-sen University Cancer Center Guangzhou Guangdong 510060 P. R. China 307 Hospital of PLA Beijing 100071 P. R. China Guangzhou Nanfang Hospital Guangzhou Guangdong 510515 P. R. China Cancer Institute ＆ Hospital Chinese Academy of Medical Sciences Beijing 100021 P. R China Shanghai First People＇s Hospital Shanghai 201620 P. R. China Beijing Cancer Hospital Beijing 100142 P. R. China Tongji Hospital Tongji Medical College of Huazhong University of Science ＆ Technology Wuhan Hubei 430030 P. R. China Tianjin Medical University Cancer Institute and Hospital Tianjin 300060 P. R. China The Affiliated Hospital of Medical College qingdao University Qingdao Shandong 266021 P. R. China Third Affiliated Hospital Third Military Medical University of People＇s Liberation Army Chongqing 400042 P. R. China The 81 Hospital of People＇s Liberation Army Nanjing Jiangsu 210002 P. R. China Shanghai Changzheng Hospital Shanghai 200003 P. R. China Roche Product Development in Asia Pacific Shanghai 201203 P. R. China.

The efficacy and safety of bevacizumab with modified irinotecan,leucovorin bolus,and 5-fluorouracil intravenous infusion(mIFL) in the first-line treatment of metastatic colorectal cancer(mCRC) has not been well evaluated in randomized clinical trials in Chinese *** conducted a phrase Ⅲ trial in which patients with previously untreated mCRC were randomized 2:1 to the mIFL [irinotecan(125 mg/m2),leucovorin(20 mg/m2) bolus,and 5-fluorouracil intravenous infusion(500 mg/m2) weekly for four weeks every six weeks] plus bevacizumab(5 mg/kg every two weeks) group and the mIFL group,***-primary objectives were progression-free survival(PFS) and 6-month PFS *** total,214 patients were *** results showed that addition of bevacizumab to mIFL significantly improved median PFS(4.2 months in the mIFL group vs.8.3 months in the bevacizumab plus mIFL group,P < 0.001),6-month PFS rate(25.0% vs.62.6%,P < 0.001),median overall survival(13.4 months vs.18.7 months,P = 0.014),and response rate(17% vs.35%,P = 0.013).Grades 3 and 4 adverse events included diarrhea(21% in the mIFL group and 26% in the bevacizumab plus mIFL group) and neutropenia(19% in the mIFL group and 33% in the bevacizumab plus mIFL group).No wound-healing complications or congestive heart failure *** results suggested that bevacizumab plus mIFL is effective and well tolerated as first-line treatment for Chinese patients with *** benefit and safety profiles were consistent with those observed in pivotal phase Ⅲ trials with mainly Caucasian patients.

关键词：结直肠癌转移性安全性 III 单抗患者随机中国